Clinical Proteomic Research for the Brain

Clinical Proteomic Research on the Brain

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00983723

Acronym

CPR Brain

Enrollment

750

Registered

2009-09-24

Start date

2005-07-31

Completion date

2016-07-31

Last updated

2013-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Individual, Ischemic Brain Injury, Neurovascular Injury, Patent Foramen Ovale (PFO), Stroke

Keywords

Patient Foramen Ovale, PFO, Stroke, Ischemic Brain Injury, Neurovascular Disease

Brief summary

The study of plasma and urine proteomic profiles in patients with ischemic brain injury is important to better understanding of the mechanisms by which thrombolytic agents or other therapy affects clinical outcomes. The purpose of this study is to study the proteomic profile of patients with ischemic brain injury and compare it to control subjects without ischemic brain injury, subjects with other chronic neurologic diseases or systemic vascular diseases, and pre- and post- therapy which may be associated with, or predictive of, therapeutic outcome. The investigators hypothesize that there is a unique set of proteins expressed in serum and urine in patients with ischemic brain injury that may provide a more complete understanding of ischemic brain injury pathophysiology. Ultimately, this study may provide information of direct relevance to the medical care of a large proportion of patients with ischemic brain injury and other neurologic diseases in the future. And proteomic proteomic profile may provide important information about the roles of specific biomarkers. Perhaps the prevention of ischemic injury related complications.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

Case Inclusion and

Exclusion criteria

Inclusion Criteria: 1. Ischemic brain injury within 12 hours of symptom onset; 2. Including primary ischemic brain injury from embolism or arterial occlusion or secondary due to increased ICP after trauma, subarachnoid hemorrhage.

Design outcomes

Primary

Measure	Time frame
Clinical Outcome and Biomarker Outcome	—

Countries

United States

Contacts

Primary ContactMingMing Ning, M.D. (PI)

CPRBrain@mgh.harvard.edu617-726-8459

Outcome results